Treatment of cystic fibrosis and other rare lung diseases / Arata Azuma, Michael S. Schechter, editors.
Contributor(s): Azuma, Arata,, editor literario | Schechter, Michael S.,, editor literario
Material type:
E-bookSeries: (Milestones in drug therapy, 2296-6056).Publisher: Switzerland : Springer, 2017Description: 1 recurso en línea.ISBN: 3034809778; 9783034809771.Subject: Fibrosis quística
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RC858.C95 T743 2017 EB (Browse shelf(Opens below)) | Acceso electrónico | eBook.20022910 |
Browsing Madrid Digital shelves, Shelving location: Acceso Electrónico (UEM) Close shelf browser (Hides shelf browser)
| RC858.C95 2020 EB Cystic Fibrosis : A Multi-Organ System Approach | RC858.C95 F553 2016 EB Handbook of Cystic Fibrosis | RC858.C95 N887 2015 EB Nutrition in Cystic Fibrosis : A Guide for Clinicians | RC858.C95 T743 2017 EB Treatment of cystic fibrosis and other rare lung diseases | RC858.P35 A986 2015 EB Autoimmune Pancreatitis | RC858.P35 .C44 2017 EB Chronic pancreatitis : from basic research to clinical treatment | RC858.P35 P743 2015 EB Prediction and Management of Severe Acute Pancreatitis |
SpringerLink Springer Biomedical and Life Sciences eBooks 2017 English+International
Incluye referencias bibliográficas
Part I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
There are no comments on this title.